Melanoma & Skin Cancer

Patients with a primary cutaneous melanoma thicker than 2 mm can be safely treated with a 2-cm resection margin.

NICE has issued a draft recommendation against Yervoy approval, stating it does not show benefits to justify its costs.

Some cosmetologists and barbers inspect their customers' scalps, necks, and faces for the presence of skin lesions that they think may be cancerous.

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Dr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

The tumor suppressor gene PTEN has been linked to the removal of DNA damage from UVB radiation, a major risk factor in the development of skin cancer.

Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial

Sun exposure to usually-covered skin is yet another risk for skin cancer.

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.

Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies